KRAS and neoplasm: Similar to the Yale team, McHenry claimed that KRAS mutation status in primary sBOTs indicates worse disease-free survival, independent of histological subtype or tumour stage or the presence of extraovarian disease, concluding that sBOT disease with a KRAS mutant pattern indicates a perhaps more aggressive biological entity with a higher likelihood of recurrence [87].